Stimulating both major branches of the immune system halts tumor growth more effectively

April 14, 2015 by Anne Trafton
An illustration of T Lymphocytes on a Cancer Cell. Credit: iStock

The human immune system is poised to spring into action at the first sign of a foreign invader, but it often fails to eliminate tumors that arise from the body's own cells. Cancer biologists hope to harness that untapped power using an approach known as cancer immunotherapy.

Orchestrating a successful immune attack against tumors has proven difficult so far, but a new study from MIT suggests that such therapies could be improved by simultaneously activating both arms of the . Until now, most researchers have focused on one of two strategies: attacking tumors with antibodies, which activate the innate immune system, or stimulating T cells, which form the backbone of the adaptive immune system.

By combining these approaches, the MIT team was able to halt the growth of a very aggressive form of melanoma in mice.

"An anti-tumor antibody can improve adoptive T-cell therapy to a surprising extent," says Dane Wittrup, the Carbon P. Dubbs Professor in Chemical Engineering at MIT. "These two different parts of the are interdependent and synergistic."

Wittrup, an associate director of MIT's Koch Institute for Integrative Cancer Research and also a faculty member in the Department of Biological Engineering, is the senior author of a paper describing the work this week in the journal Cancer Cell. Lead authors are graduate students Eric Zhu and Cary Opel and recent PhD recipient Shuning Gai.

Enlisting the immune system

Antibody drugs for cancer, which include rituximab and Herceptin, are believed to work by binding to cancer proteins and blocking the signals that tell to divide uncontrollably. They may also draw the attention of cells belonging to the innate immune system, such as natural killer cells, which can destroy .

Adoptive T cell therapy, on the other hand, enlists the body's T cells to attack tumors. Billions of T cells flow through the average person's bloodstream at any given time, each specialized to recognize different molecules. However, many tumor proteins do not provoke T cells to attack, so T cells must be removed from the patient and programmed to attack a specific tumor molecule.

Wittrup and his colleagues made the discovery that they could generate both types of immune responses while they were experimenting with improving antibody drug performance with a signaling molecule called IL-2, which helps boost immune responses.

Scientists have tried this strategy before, and about a dozen such therapies have gone through phase I clinical trials. However, most of these efforts failed, even though the antibody-IL-2 combination usually works very well against cancer cells grown in a lab dish.

The MIT team realized that this failure might be caused by the timing of IL-2 delivery. When delivered to cells in a dish, IL-2 sticks around for a long time, amplifying the response of natural killer cells against cancer cells. However, when IL-2 is injected into a patient's bloodstream, the kidneys filter it out within an hour.

Wittrup and his colleagues overcame this by fusing IL-2 to part of an antibody molecule, which allows it to circulate in the bloodstream for much longer. In tests in mice with a very aggressive form of melanoma, the researchers found they could stop by delivering this engineered form of IL-2, along with antibody drugs, once a week.

Immune synergy

To their surprise, the researchers found that T cells were the most important component of the anti-tumor response induced by the antibody-IL-2 combination. They believe that the synergy of IL-2-induced cells and cytokines, and the antibody treatment, creates an environment that lets T cells attack more effectively.

"The antibody-driven innate response creates an environment such that when the T cells come in, they can kill the tumor. In its absence, the tumor cells establish an environment where the T cells don't work very well," Wittrup says.

Cells called neutrophils, which are considered the immune system's "first line of defense" because they react strongly to foreign invaders that enter the skin through a cut or other injury, were also surprisingly important.

"They're a really powerful force in your immune system, but people in immunotherapy don't usually focus on neutrophils. They don't really consider them as a viable tool," Zhu says. "It pointed us to the idea that although T cells and are important, maybe we're forgetting about a part of the immune system that is also really important and could help us achieve our goals of ultimately curing the tumors."

The researchers also found that when they delivered an antibody, IL-2, and T cells targeted to the tumor, the adoptively transferred T cells killed cancer cells much more successfully than when only T cells were delivered. In 80 to 90 percent of the mice, tumors disappeared completely; even when tumor cells were reinjected into the mice months after the original treatment, their immune systems destroyed the , preventing new tumors from forming

In a related paper that appeared recently in the Proceedings of the National Academy of Science, the MIT team also found that delivering IL-2 bound to any kind of antibody, even if the antibody did not target a protein on the tumor cell surface, would halt or slow tumor growth, especially if additional doses of the antibody alone were also given. Graduate student Alice Tzeng was the lead author of that study.

The researchers are now exploring additional proteins that could be added to the IL-2 and antibody combination to make immunotherapy more effective. In the meantime, simply giving patients more prolonged exposure to IL-2 could improve the effectiveness of existing antibody drugs, Wittrup says.

Explore further: Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker

More information: "Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2" Cancer Cell, DOI: dx.doi.org/10.1016/j.ccell.2015.03.004

Related Stories

Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker

November 26, 2014
A promising experimental immunotherapy drug works best in patients whose immune defenses initially rally to attack the cancer but then are stymied by a molecular brake that shuts down the response, according to a new study ...

Promising new strategy to halt pancreatic cancer metastasis

March 2, 2015
Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.

A novel immunotherapy technique to treat patients with osteosarcoma and neuroblastoma

February 26, 2015
A novel phase 1 clinical trial that leverages T-cell immunotherapy is now under way at Karmanos Cancer Institute (KCI) in Detroit and Memorial Sloan-Kettering Cancer Center in New York City; bringing new hope to children ...

Cancer vaccine could use immune system to fight tumors

February 27, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Cytokine therapy enhances natural killer cell functions against tumor cells

October 20, 2014
Natural killer (NK) cells are sentinels within the immune system that rapidly respond to and kill diseased cells. NK cells typically target and eliminate cells lacking the surface protein MHC class I. However, many tumor ...

Getting antibodies into shape to fight cancer

December 11, 2014
Scientists at the University of Southampton have found that the precise shape of an antibody makes a big difference to how it can stimulate the body's immune system to fight cancer, paving the way for much more effective ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

furbush87
not rated yet Apr 14, 2015
Probably be a better match with either T-Vec, Lion bio-pharmaceutical's TIL, or electroporated IL-12.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.